$KALV News

KalVista Pharmaceuticals Announces New Data That Highlight Burden Of Injectable On-Demand Treatment In Children Aged 2–11 With Hereditary Angioedema

A Look At KalVista Pharmaceuticals (KALV) Valuation After A Strong Year Of Share Price Gains

HC Wainwright & Co. Downgrades KalVista Pharmaceuticals to Neutral, Lowers Price Target to $27

Needham Downgrades KalVista Pharmaceuticals to Hold

Chiesi widens rare disease portfolio with $1.9bn KalVista buyout

IBT portfolio manager says KalVista deal signals Biotech 2.0 growth

Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement

KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too

KalVista: 'Strong Buy' As Acquired By Chiesi And Positive KONFIDENT-KID Outcome

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

Chiesi to buy KalVista in $1.9B deal for rare disease drug

KalVista Pharmaceuticals shares are trading higher after the company announced it will be acquired by Chiesi Group

Chiesi Group Signs Agreement To Acquire KalVista Pharmaceuticals For $27/Share In Cash

KalVista Pharmaceuticals Touts EKTERLY Launch: Nearly $50M in Under 6 Months, 20% Patient Reach

KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals (KALV) Is Up 22.4% After Early Success In Pivotal Pediatric HAE Trial

KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference

KalVista Pharma Presents New Interim Results From KONFIDENT-KID Clinical Trial Evaluating EKTERLY For On-Demand Treatment Of HAE Attacks In Children Ages 2-11 At 2026 Global Angioedema Leadership Conference